Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Abbreviations and acronyms1. Preamble2. Introduction 2.1 Short- and long-term outcomes after percutaneous coronary intervention 2.2 Risk of stent thrombosis in relation to stent type 2.3 Short- and long-term outcomes after coronary artery bypass surgery 2.4 Short- and long-term outcomes after medically managed acute coronary syndrome3. Efficacy and safety of dual antiplatelet therapy and risk stratification tools 3.1 DAPT for the prevention of stent thrombosis 3.2 DAPT for the prevention of spontaneous myocardial infarction 3.3 DAPT and mortality rate 3.4 Safety of DAPT 3.5 Risk stratification tools for ischaemia and bleeding risks3.6 Type of P2Y12 inhibitor and timing of initiation3.7 Measures to minimize bleeding while on DAPT3.8 Switching between oral P2Y12 inhibitors4. DAPT and percutaneous coronary intervention 4.1 DAPT after percutaneous coronary intervention for stable coronary artery disease 4.2 DAPT after percutaneous coronary intervention for acute coronary syndrome 4.3 Gaps in evidence5. DAPT and cardiac surgery 5.1 DAPT in patients treated with coronary artery bypass surgery for stable coronary artery disease 5.2 DAPT in patients treated with coronary artery bypass surgery for acute coronary syndrome 5.3 DAPT for prevention of graft occlusion 5.4 Gaps in evidence6. DAPT for patients with medically managed acute coronary syndrome7. DAPT for patients with indication for oral anticoagulation 7.1 Risk stratification and strategies to improve outcome after percutaneous coronary intervention 7.2 Duration of triple therapy 7.3 Cessation of all antiplatelet agents 7.4 Type of anticoagulants 7.5 Type of stent8. Elective non-cardiac surgery in patients on DAPT9. Gender consideration and special populations 9.1 Gender specificities 9.2 Diabetes mellitus 9.3 Lower-extremities artery disease 9.4 Complex percutaneous coronary intervention 9.5 DAPT decision making in patients with stent thrombosis 9.6 Patients who develop bleeding while on treatment10. Key Messages11. Evidenced-based “To do and not to do” messages12. Web addenda and Clinical Cases companion document13. Appendix14. References
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved